353 related articles for article (PubMed ID: 28751445)
1. Head and Neck Carcinoma Immunotherapy: Facts and Hopes.
Whiteside TL
Clin Cancer Res; 2018 Jan; 24(1):6-13. PubMed ID: 28751445
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic Approaches to Head and Neck Cancer.
Nasser H; St John M
Crit Rev Oncog; 2018; 23(3-4):161-171. PubMed ID: 30311572
[TBL] [Abstract][Full Text] [Related]
3. The biology of combination immunotherapy in recurrent metastatic head and neck cancer.
Yuan X; Yi M; Zhang W; Xu L; Chu Q; Luo S; Wu K
Int J Biochem Cell Biol; 2021 Jul; 136():106002. PubMed ID: 33962022
[TBL] [Abstract][Full Text] [Related]
4. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB
Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
6. Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.
Ludwig S; Floros T; Theodoraki MN; Hong CS; Jackson EK; Lang S; Whiteside TL
Clin Cancer Res; 2017 Aug; 23(16):4843-4854. PubMed ID: 28400428
[No Abstract] [Full Text] [Related]
7. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment.
Ruffin AT; Li H; Vujanovic L; Zandberg DP; Ferris RL; Bruno TC
Nat Rev Cancer; 2023 Mar; 23(3):173-188. PubMed ID: 36456755
[TBL] [Abstract][Full Text] [Related]
8. [Current events in immunotherapy for upper aerodigestive tract cancer].
Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
[TBL] [Abstract][Full Text] [Related]
9. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
10. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
11. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
[TBL] [Abstract][Full Text] [Related]
12. Potential oncogenic roles of mutant-p53-derived exosomes in the tumor-host interaction of head and neck cancers.
Azulay EE; Cooks T; Elkabets M
Cancer Immunol Immunother; 2020 Feb; 69(2):285-292. PubMed ID: 31897662
[TBL] [Abstract][Full Text] [Related]
13. Promising systemic immunotherapies in head and neck squamous cell carcinoma.
Gildener-Leapman N; Ferris RL; Bauman JE
Oral Oncol; 2013 Dec; 49(12):1089-96. PubMed ID: 24126223
[TBL] [Abstract][Full Text] [Related]
14. Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.
Horton JD; Knochelmann HM; Day TA; Paulos CM; Neskey DM
Trends Cancer; 2019 Apr; 5(4):208-232. PubMed ID: 30961829
[TBL] [Abstract][Full Text] [Related]
15. DNA-based immunotherapy for HPV-associated head and neck cancer.
Aggarwal C
Immunotherapy; 2016 Oct; 8(10):1187-92. PubMed ID: 27605067
[TBL] [Abstract][Full Text] [Related]
16. Immunobiology and immunotherapy of head and neck cancer.
Whiteside TL
Curr Oncol Rep; 2001 Jan; 3(1):46-55. PubMed ID: 11123869
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
[TBL] [Abstract][Full Text] [Related]
18. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.
Seliger B; Massa C; Yang B; Bethmann D; Kappler M; Eckert AW; Wickenhauser C
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987799
[TBL] [Abstract][Full Text] [Related]
19. The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.
Freiser ME; Serafini P; Weed DT
Immunol Res; 2013 Dec; 57(1-3):52-69. PubMed ID: 24218361
[TBL] [Abstract][Full Text] [Related]
20. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]